Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662 Reck, 2019, Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater, J Clin Oncol, 37, 537, 10.1200/JCO.18.00149 Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795 Ward, 2019, Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years, J Natl Cancer Inst, 111, 1279, 10.1093/jnci/djz106 Howlader, 2020, The effect of advances in lung-cancer treatment on population mortality, N Engl J Med, 383, 640, 10.1056/NEJMoa1916623 Wu, 2020, Osimertinib in resected EGFR-mutated non-small-cell lung cancer, N Engl J Med, 383, 1711, 10.1056/NEJMoa2027071 Wakelee, 2021, IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC), J Clin Oncol, 39 Forde, 2022, Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer, N Engl J Med, 386, 1973, 10.1056/NEJMoa2202170 Grose, 2014, Comorbidities in lung cancer: prevalence, severity and links with socioeconomic status and treatment, Postgrad Med J, 90, 305, 10.1136/postgradmedj-2013-132186 Tammemagi, 2003, Impact of comorbidity on lung cancer survival, Int J Cancer, 103, 792, 10.1002/ijc.10882 Leduc, 2017, Comorbidities in the management of patients with lung cancer, Eur Respir J, 49, 10.1183/13993003.01721-2016 Birim, 2005, Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer, Eur J Cardiothorac Surg, 28, 759, 10.1016/j.ejcts.2005.06.046 Asmis, 2008, Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials, J Clin Oncol, 26, 54, 10.1200/JCO.2007.12.8322 Islam, 2015, Comorbidity and survival in lung cancer patients, Cancer Epidemiol Biomarkers Prev, 24, 1079, 10.1158/1055-9965.EPI-15-0036 Iachina, 2015, The effect of different comorbidities on survival of non-small cells lung cancer patients, Lung, 193, 291, 10.1007/s00408-014-9675-5 Deleuran, 2013, Comorbidity and survival of Danish lung cancer patients from 2000–2011: a population-based cohort study, Clin Epidemiol, 5, 31, 10.2147/CLEP.S47473 The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia | Epidemiology & infection. Cambridge Core. https://www.cambridge.org/core/journals/epidemiology-and-infection/article/updated-charlson-comorbidity-index-is-a-useful-predictor-of-mortality-in-patients-with-staphylococcus-aureus-bacteraemia/EB5C7C12D4FAACE25B38B1E7B9A79FEF. Accessed July 8, 2021. Ganti, 2011, Predictive ability of Charlson comorbidity index on outcomes from lung cancer, Am J Clin Oncol, 34, 593, 10.1097/COC.0b013e3181fe445b Timmerman, 2010, Stereotactic body radiation therapy for inoperable early stage lung cancer, JAMA, 303, 1070, 10.1001/jama.2010.261 Carver, 2007, American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects, J Clin Oncol, 25, 3991, 10.1200/JCO.2007.10.9777 Sekine, 2002, Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC, Lung Cancer, 37, 95, 10.1016/S0169-5002(02)00014-4 Bobbio, 2008, Preoperative pulmonary rehabilitation in patients undergoing lung resection for non-small cell lung cancer, Eur J Cardiothorac Surg, 33, 95, 10.1016/j.ejcts.2007.10.003 Templeton, 2019, Preoperative rehabilitation for thoracic surgery, Curr Opin Anaesthesiol, 32, 23, 10.1097/ACO.0000000000000668 Daly, 2022, Inoperable early-stage non–small-cell lung cancer: stereotactic ablative radiotherapy and rationale for systemic therapy, J Clin Oncol, 40, 539, 10.1200/JCO.21.01611 Takenaka, 2013, The impact of cardiovascular comorbidities on the outcome of surgery for non-small-cell lung cancer, Interact Cardiovasc Thorac Surg, 16, 270, 10.1093/icvts/ivs489 Hardy, 2010, Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer, Ann Oncol, 21, 1825, 10.1093/annonc/mdq042 Belzile-Dugas, 2021, Radiation-induced cardiovascular disease: review of an underrecognized pathology, J Am Heart Assoc, 10 Wang, 2017, Cardiac toxicity after radiotherapy for stage III non–small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy, J Clin Oncol, 35, 1387, 10.1200/JCO.2016.70.0229 Le Pechoux, 2022, Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3, Lancet Oncol, 23, 104, 10.1016/S1470-2045(21)00606-9